Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

PURPOSE: The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically useful tests. We report findings from the Lung Adjuvant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Devarakonda, Siddhartha, Rotolo, Federico, Tsao, Ming-Sound, Lanc, Irena, Brambilla, Elisabeth, Masood, Ashiq, Olaussen, Ken A., Fulton, Robert, Sakashita, Shingo, McLeer-Florin, Anne, Ding, Keyue, Le Teuff, Gwénaël, Shepherd, Frances A., Pignon, Jean-Pierre, Graziano, Stephen L., Kratzke, Robert, Soria, Jean-Charles, Seymour, Lesley, Govindan, Ramaswamy, Michiels, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804865/
https://ncbi.nlm.nih.gov/pubmed/30106638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.78.1963
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados